Cargando…

The Prognostic Signature and Therapeutic Value of Phagocytic Regulatory Factors in Prostate Adenocarcinoma (PRAD)

There is growing evidence that phagocytosis regulatory factors (PRFs) play important roles in tumor progression, and therefore, identifying and characterizing these factors is crucial for understanding the mechanisms of cellular phagocytosis in tumorigenesis. Our research aimed to comprehensively ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Xin, Shiyong, Sun, Xianchao, Jin, Liang, Li, Weiyi, Liu, Xiang, Zhou, Liqing, Ye, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9190300/
https://www.ncbi.nlm.nih.gov/pubmed/35706452
http://dx.doi.org/10.3389/fgene.2022.877278
_version_ 1784725757467033600
author Xin, Shiyong
Sun, Xianchao
Jin, Liang
Li, Weiyi
Liu, Xiang
Zhou, Liqing
Ye, Lin
author_facet Xin, Shiyong
Sun, Xianchao
Jin, Liang
Li, Weiyi
Liu, Xiang
Zhou, Liqing
Ye, Lin
author_sort Xin, Shiyong
collection PubMed
description There is growing evidence that phagocytosis regulatory factors (PRFs) play important roles in tumor progression, and therefore, identifying and characterizing these factors is crucial for understanding the mechanisms of cellular phagocytosis in tumorigenesis. Our research aimed to comprehensively characterize PRFs in prostate adenocarcinoma (PRAD) and to screen and determine important PRFs in PRAD which may help to inform tumor prognostic and therapeutic signatures based on these key PRFs. Here, we first systematically described the expression of PRFs in PRAD and evaluated their expression patterns and their prognostic value. We then analyzed prognostic phagocytic factors by Cox and Lasso analysis and constructed a phagocytic factor-mediated risk score. We then divided the samples into two groups with significant differences in overall survival (OS) based on the risk score. Then, we performed correlation analysis between the risk score and clinical features, immune infiltration levels, immune characteristics, immune checkpoint expression, IC50 of several classical sensitive drugs, and immunotherapy efficacy. Finally, the Human Protein Atlas (HPA) database was used to determine the protein expression of 18 PRF characteristic genes. The aforementioned results confirmed that multilayer alterations of PRFs were associated with the prognosis of patients with PRAD and the degree of macrophage infiltration. These findings may provide us with potential new therapies for PRAD.
format Online
Article
Text
id pubmed-9190300
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91903002022-06-14 The Prognostic Signature and Therapeutic Value of Phagocytic Regulatory Factors in Prostate Adenocarcinoma (PRAD) Xin, Shiyong Sun, Xianchao Jin, Liang Li, Weiyi Liu, Xiang Zhou, Liqing Ye, Lin Front Genet Genetics There is growing evidence that phagocytosis regulatory factors (PRFs) play important roles in tumor progression, and therefore, identifying and characterizing these factors is crucial for understanding the mechanisms of cellular phagocytosis in tumorigenesis. Our research aimed to comprehensively characterize PRFs in prostate adenocarcinoma (PRAD) and to screen and determine important PRFs in PRAD which may help to inform tumor prognostic and therapeutic signatures based on these key PRFs. Here, we first systematically described the expression of PRFs in PRAD and evaluated their expression patterns and their prognostic value. We then analyzed prognostic phagocytic factors by Cox and Lasso analysis and constructed a phagocytic factor-mediated risk score. We then divided the samples into two groups with significant differences in overall survival (OS) based on the risk score. Then, we performed correlation analysis between the risk score and clinical features, immune infiltration levels, immune characteristics, immune checkpoint expression, IC50 of several classical sensitive drugs, and immunotherapy efficacy. Finally, the Human Protein Atlas (HPA) database was used to determine the protein expression of 18 PRF characteristic genes. The aforementioned results confirmed that multilayer alterations of PRFs were associated with the prognosis of patients with PRAD and the degree of macrophage infiltration. These findings may provide us with potential new therapies for PRAD. Frontiers Media S.A. 2022-05-30 /pmc/articles/PMC9190300/ /pubmed/35706452 http://dx.doi.org/10.3389/fgene.2022.877278 Text en Copyright © 2022 Xin, Sun, Jin, Li, Liu, Zhou and Ye. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Xin, Shiyong
Sun, Xianchao
Jin, Liang
Li, Weiyi
Liu, Xiang
Zhou, Liqing
Ye, Lin
The Prognostic Signature and Therapeutic Value of Phagocytic Regulatory Factors in Prostate Adenocarcinoma (PRAD)
title The Prognostic Signature and Therapeutic Value of Phagocytic Regulatory Factors in Prostate Adenocarcinoma (PRAD)
title_full The Prognostic Signature and Therapeutic Value of Phagocytic Regulatory Factors in Prostate Adenocarcinoma (PRAD)
title_fullStr The Prognostic Signature and Therapeutic Value of Phagocytic Regulatory Factors in Prostate Adenocarcinoma (PRAD)
title_full_unstemmed The Prognostic Signature and Therapeutic Value of Phagocytic Regulatory Factors in Prostate Adenocarcinoma (PRAD)
title_short The Prognostic Signature and Therapeutic Value of Phagocytic Regulatory Factors in Prostate Adenocarcinoma (PRAD)
title_sort prognostic signature and therapeutic value of phagocytic regulatory factors in prostate adenocarcinoma (prad)
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9190300/
https://www.ncbi.nlm.nih.gov/pubmed/35706452
http://dx.doi.org/10.3389/fgene.2022.877278
work_keys_str_mv AT xinshiyong theprognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad
AT sunxianchao theprognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad
AT jinliang theprognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad
AT liweiyi theprognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad
AT liuxiang theprognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad
AT zhouliqing theprognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad
AT yelin theprognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad
AT xinshiyong prognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad
AT sunxianchao prognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad
AT jinliang prognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad
AT liweiyi prognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad
AT liuxiang prognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad
AT zhouliqing prognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad
AT yelin prognosticsignatureandtherapeuticvalueofphagocyticregulatoryfactorsinprostateadenocarcinomaprad